Scholarlink

<p>Given the scarcity of studies predicting iodine-131 treatment failure based on clinicopathological factors, this study aimed to determine whether clinicopathological features can predict iodine-131 treatment failure in differentiated thyroid carcinoma (DTC) patients. A total of 182 patients were analyzed, including 114 with favorable outcomes and 68 with resistance or poor outcomes. Patients were split into a training set (122 patients) and a validation set (60 patients). Logistic regression identified the number of lateral neck lymph node metastases (<i>P</i> = 0.001) and pre-radioactive iodine therapy serum thyroglobulin levels (<i>P</i> = 0.001) as independent predictors of treatment failure. The predictive model, visualized via a nomogram, achieved area under curves (AUCs) of 0.838 (95% CI, 0.759–0.917) and 0.766 (95% CI, 0.626–0.905) in the training and validation sets, respectively. Calibration curves showed good agreement between predicted and observed outcomes, and decision curve analysis confirmed the model’s clinical utility. Subgroup analyses yielded AUCs of 0.777 (95% CI, 0.648–0.906), 0.745 (95% CI, 0.646–0.843), 0.734 (95% CI, 0.649–0.820), and 0.911 (95% CI, 0.769–0.999) for male, female, age &lt; 55, and age ≥ 55 groups, respectively. This model effectively predicts iodine-131 treatment failure risk in DTC patients, providing valuable information for clinical decision-making.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development and validation of a nomogram to predict failure of initial radioactive iodine therapy in differentiated thyroid cancer: a retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月21日

查看全文
  • Yulong Tang,
  • Peng Wu,
  • Shiwei Zhou,
  • Hui Li,
  • Xiaohua Song,
  • Wu Li,
  • Xiaowei Peng

摘要

Given the scarcity of studies predicting iodine-131 treatment failure based on clinicopathological factors, this study aimed to determine whether clinicopathological features can predict iodine-131 treatment failure in differentiated thyroid carcinoma (DTC) patients. A total of 182 patients were analyzed, including 114 with favorable outcomes and 68 with resistance or poor outcomes. Patients were split into a training set (122 patients) and a validation set (60 patients). Logistic regression identified the number of lateral neck lymph node metastases (P = 0.001) and pre-radioactive iodine therapy serum thyroglobulin levels (P = 0.001) as independent predictors of treatment failure. The predictive model, visualized via a nomogram, achieved area under curves (AUCs) of 0.838 (95% CI, 0.759–0.917) and 0.766 (95% CI, 0.626–0.905) in the training and validation sets, respectively. Calibration curves showed good agreement between predicted and observed outcomes, and decision curve analysis confirmed the model’s clinical utility. Subgroup analyses yielded AUCs of 0.777 (95% CI, 0.648–0.906), 0.745 (95% CI, 0.646–0.843), 0.734 (95% CI, 0.649–0.820), and 0.911 (95% CI, 0.769–0.999) for male, female, age < 55, and age ≥ 55 groups, respectively. This model effectively predicts iodine-131 treatment failure risk in DTC patients, providing valuable information for clinical decision-making.